$RGEN · REPLIGEN CORP
Repligen filed its Q3 2026 10-Q, reporting $209.3M in total revenue (+10.9% YoY) and a GAAP net loss of $38.4M ($0.68/share). The loss was driven primarily by a $41.2M intangible asset impairment charge. The company also disclosed the pending $1.9B acquisition of BioLife Solutions, expected to close in Q4 2026, to be accounted for in that period.
- Q3 revenue rose 10.9% YoY to $209.3M, with product revenue up across all franchises.
- GAAP net loss of $38.4M ($0.68/share) driven by a $41.2M intangible asset impairment charge.
- Gross margin compressed as cost of goods sold grew to $98.3M from $88.3M in Q3 2025.
- Operating loss of $29.5M vs. $16.8M operating income in the prior-year quarter.
- Announced $1.9B BioLife Solutions acquisition (7.2M shares + $564M cash), closing in Q4 2026.
Stock down 6.2% in regular session to $176.94; extended-hours last trade at $177.00 shows negligible (+0.03%) after-hours movement, suggesting the impairment-driven loss was largely priced in during the regular session.
A $41.2M impairment charge turning solid revenue growth into a deep net loss, paired with a transformative $1.9B acquisition on deck, makes this a pivotal quarter for Repligen.
Repligen's 10.9% organic revenue growth contrasts with the impairment charge, reflecting a broader bioprocessing sector pattern where demand recovery coexists with asset-valuation resets. The BioLife deal mirrors ongoing consolidation among life-sciences tools suppliers.
The $41.2M intangible asset impairment signals potential overpayment for prior acquisitions; combined with the $1.9B BioLife deal closing in Q4, integration and goodwill risk is elevated. Foreign currency translation losses of $22.8M YTD add macro exposure.